Metacenter Therapeutics (CEO Park Myung-kyu), a new glycotoxin drug development company, has proven the glycotoxin-reducing efficacy of KF140 lactobacillus, and has decided to start aggressive marketing from 2023 to enter the global market from North America to Europe. In June 2022, Metacenter Therapeutics said that the research results of Lactococcus lactis KF140 (hereinafter referred to […]
